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Are children with cystic fibrosis of 4 to 6 years able to use dry 
powder inhalers: The effect of varying resistance on inspiratory 
volumes and flows 
H.A.WM.  Tiddens, T. van der Zanden 
Department of Pediatric Pulmo~u~logy arm Allergology, Erasrm*s MC-Sophia, 
Rotterdam, The Netherlands 
The t ime burden for daily nebulizer therapy is considerable for CF patients. Dry 
Powder Inhalers (DPI) are being developed for the inhalation of antibiotics. 
Inhalation f low rate and device resistance (Rd) interact to disperse drug from a DPI. 
Most children of >6 years are able to inhale with an inspiratory flow >30 LPM or 
higher mad with inspired volume (V) >1 L. A im:  To assess the feasibility of CF 
patients of 4 to 6 years to use DPIs effectively Methods: 6 stable CF patients, age 4 
to 6 years, were enrolled to date. Subjects hahaled 3 times forcefully through 4 
different R d (0.05, 0.07, 0.12, 0.17 cmIt~O°5/L/min) whi le  inspiratory t ime (IT), 
peak inspiratory flow (PIF), mean inspiratory f low (MIF) and V were measured. 
Results mean (+SD): V was 0.7(+0.23), 0.69(+0.29), 0.58(+0.31), 0.57(+0.29) L, 
PIF 68(+17), 61(+ 19), 50(+12), 44(+8.1) LPM, MIF (40.4+11.3), 37.6(+13.4), 
33(+7.7) 29(+6.7) LPM, IT 1.06(+0.46), 1.09(+0.44), 0.98(+0.5), 1.12 (+0.54) sec 
for, R d 0.05, 0.07, 0.12, and 0.17 cmIt~O° 5/L/rain, respectively. There was a linear 
relation between MIF and V. V was above 1 L ha only 2 out of 72 inspiratory 
maneuvers. Conclusion: CF patients 4 to 6 years are probably able to generate 
inspiratory flows between 30 and 60 LPM though most DPIs. The inspiratory 
volume is critically low to empty a high drug load in a single inhalation. Based on 
these results it is questionable whether the DPI can be us d to treat he 4 to 6 age 
old CF patients with inhaled antibiotics. 
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Patient saSsfacSon with individualized controlled breathing 
A. Fischer, T. Schiefer 
Inamed GmbH, Germ~nde~ Germany 
Success of the inhalation treatment in CF highly depends on patients' satisfaction 
and compliance with the prescribed treatment scheme. Inhalation t ime is regarded 
to be a major factor impacting compliance. Most newly developed nebulizers 
approach treatment t ime by optimizing the aerosol generation (to improve output). 
The AKITA ® inhalation system follows a different approach by optimizing lung 
deposition. The number of breaths per treatment are determined and the inspiration 
of the patients is controlled by inducing a slow and constant flow. 
A im of this study was to evaluate the patient satisfaction and inhalation times with 
the AKITA. 
We asked 10 patients, 5m, 5f, age 29 (16 40) to document their satisfaction with the 
system by completing a questiommire. For every question it was asked to give an 
impression for 'Importance' and 'Satisfaction'. 
Patients inhale multiple (1 4) drugs with the AIGTA. Five patients mentioned that 
they continued to use their old device (e.g. on travel). Overall Satisfaction was rated 
with 'Extremely satisfied' (7) or 'Very Satisfied' (3). The controlled inspiration was 
assessed as 'Very positive' (8) or 'Get along wel l  most of the t ime' (2). Average 
Importance/Satisfaction ratings (max: 5) for selected aspects were: 'Rel iable 
Dosage' (4.4/4.4), 'Reduced Inhalation Times' (3.9/4.4), 'Transport' (3.8/2.5). 
Patients assessed treatment times with AKITA about 40% (12% 62%) shorter, 
compared to the former nebulizer (8 Pari Master). 
H igh satisfaction rates among CF patients indicate the good acceptance of 
individulaized controlled inhalation. Patients appreciate shorter inhalations due to 
the high efficiency of the system. Interestingly, the benefit of t ime saving is not 
rated as most important. More important was the reliabil ity of dosage, that is 
ensured by the individualized controlled breathing of the AKITA inhalation system. 
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Effectiveness and safety of nib~ous oxide/oxygen mixture for 
analgesia during painful procedures in children with cystic fibrosis 
J. Lent on, C. Warde, P. Seddon 
Royal A lexandra ChiMren's Hospital, Brighton, UK
Children with cystic fibrosis often require painful procedures to be carried out on 
repeated occasions during their childhood. Many become excessively fearful of 
such prccedures. Oral or intranasal sedation is often ineffective and may have 
prolonged effects hampering physiotherapy. Inhalational analgesia using nitrous 
oxide/oxygen mixture ("Entonox') has been shown to be effective in non 
respiratory conditions, but concerns remain about its afety ha cbronic respiratory 
disease. We aimed to assess the effectiveness mad safety of this technique in children 
with cystic fibrosis. 
Methods: We measured lung function, oxygen saturation, rated pain (observed mad 
perceived) and level of sedation before, and 60 minutes after Entonox analgesia ha 
10 chi ldren with cystic fibrosis tmdergoing painful prccedures (venepuncture or
cannulation). Al l  parameters except lung function were also measured uring and at 
5 minutes after the prc~edure. Observed pain was rated using a behavioral pain 
assessment score (CHEOPS) and perceived pain using the Wong Baker Faces scale. 
Results: 
Basefine 60rain post Mean A Conf. fimita 
FEV1 (L) 1.77 1.73 0.045 0.14, +0.03 
FVC (L) 2.08 2.03 0.03 0.16, +0.06 
SaO2 (%) 97.7 98.5 +1.07 0.37, +1.17 
There were no significant changes ha lung function or oxygen saturation. 
Median CHEOPS score remained at 4 (unchanged from baseline) flaroughout the 
procedure; median Faces score increased from 0 to 1. 
Medima sedation score fel l  from 5 at baseline to 4 during procedure, but had 
returned to 5 by 5 minutes post procedure. 
Conclusions: Nitrous oxide/oxygen inhalation appears to be effective ha providing 
mmlgesia during venepuncture and line insertion in children with cystic fibrosis, 
with no evidence of adverse respkatory effects. 
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A clustering of allergic bronchopulmonary aspergillosis in a Iocalised 
cysfJc fibrosis population 
F. Healy, H. Coffey, M.J. Mahony 
Department ofPaediatrics, Limerick Regional Hospital, Limerick, h ela~M 
Aims: Most cases of allergic bronchopulmonary aspergillosis (ABPA) have been 
reported in young adults however, we report a cluster of 3 acute cases over a 2 
month period ha a regional cystic fibrosis (CF) paediatric service. Notably all 3 
cases were from a particular geographical region. 
Methods: ha October 2CO4, we reviewed all 73 paediatric CF cases attending 
Limerick Regional Hospital over the previous 3 years. Al l  cases of ABPA were 
identified as wel l  as any cases with positive Aspergillus (A.) fumigatus pecific IgE, 
or positive serum precipitans to A. fumigatus or positive sputum culture for A. 
fumigatus. 
Results: There were no cases of AEPA from September 2CO1 to July 2CO4. 
However, in August and September 2CC,4, we  identified 3 cases of AEPA, all of 
whom responded clinically to treatment. Although the paediatric CF service at 
L imerick Regional Hospital covers a large area over 5 counties, it was notable that 
all 3 cases presented from County Clare. 
In addition, 10 separate cases were noted to have elevated total and A fumigatus 
specific Ig~. A further 2 cases were noted to have positive serum precipit ans to A. 
fumigatus. A l l  12 cases remained asymptomatic of AEPA. However it is notable 
that 7 of these 12 cases were also from areas in County Clare. 
In our 3 year review we found that a total of 15 paediatric CF patients were at some 
stage exposed or reacted to A. fumigatus. O1" these, 10 (66%) were from areas in 
County Clare. This is significant when overall only 28% of our total paediatric CF 
population hail  from County Clare. 
Conclusion: We present a cluster of 3 acute cases of AEPA in a lccal is~l paediatric 
population over a 2 month period. Whether this may be attributed to increased spore 
density in the particular area has not been determined. 
